Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method"

Kazumasa Miki, Kazumasa Miki

Abstract

The current status of screening for gastric cancer-risk (gastritis A, B, C, D) method using combined assay for serum anti-Helicobacter pylori (Hp) IgG antibody and serum pepsinogen (PG) levels, "ABC method", was reviewed and the latest results of our ongoing trial are reported. It was performed using the following strategy: Subjects were classified into 1 of 4 risk groups based on the results of the two serologic tests, anti-Hp IgG antibody titers and the PG I and II levels: Group A [Hp(-)PG(-)], infection-free subjects; Group B [Hp(+)PG(-)], chronic atrophic gastritis (CAG) free or mild; Group C [Hp(+)PG(+)], CAG; Group D [Hp(-)PG(+)]), severe CAG with extensive intestinal metaplasia. Continuous endoscopic follow-up examinations are required to detect early stages of gastric cancer. Asymptomatic Group A, which accounts for 50-80% of all the subjects may be excluded from the secondary endoscopic examination, from the viewpoint of efficiency. Hp-infected subjects should be administered eradication treatment aimed at the prevention of gastric cancer.

Figures

Figure 1.
Figure 1.
Accumulated survival rate for each age-group by the PG method using Kaplan–Meier analysis at Tokyo Teishin Hospital Care Center in Tokyo for the ten-year period (1992–2001); n = 88263,64)

References

    1. Melton S.D., Genta M., Souza R.F. (2010) Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms. Nat. Rev. Gastroenterol. Hepatol. 7, 620–628
    1. Parkin D.M., Bray F., Ferlay J., Pisani P. (2005) Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74–108
    1. Correa P., Piazuelo M.B., Wilson T. (2010) Pathology of gastric intestinal metaplasia: Clinical implications. Am. J. Gastroenterol. 105, 493–498
    1. Asaka M., Kato M., Takahashi S., Fukuda Y., Sugiyama T., Ota H., Uemura N., Murakami K., Satoh K., Sugano K. (2010) Guideline for the management of Helicobacter pylori in Japan: 2009 revised edition. J. Helicobacter 15, 1–20
    1. Asaka M., Kato M., Graham D.Y. (2010) Strategy for eliminating gastric cancer in Japan. Helicobacter 15, 486–490
    1. Miki K., Ichinose M., Shimizu A., Huang S.C., Oka H., Furihata C., Matsushima T., Takahashi K. (1987) Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol. Jpn. 22, 133–141
    1. Miki K., Ichinose M., Kawamura N., Matsushima M., Ahmad H.B., Kimura M., Sano J., Tashiro T., Kakei N., Oka H., Furihata C., Takahashi K. (1989) The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. Jpn. J. Cancer Res. 80, 111–114
    1. Miki K., Ichinose M., Ishikawa K.B., Yahagi N., Matsushima M., Kakei N., Tsukada S., Kido M., Ishihama S., Shimizu Y., Suzuki T., Kurokawa K. (1993) Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn. J. Cancer Res. 84, 1086–1090
    1. Miki, K., Ichinose, M., Kakei, N., Yahagi, N., Matsushima, M., Tsukada, S., Ishihama, S., Shimizu, Y., Suzuki, T., Kurokawa, K. and Takahashi, K. (1995) The clinical application of the serum pepsinogen I and II levels as mass screening method for gastric cancer. In Aspartic Proteinases: Structure, Function, Biology and Biomedical Implications (ed. Takahashi, K.). Plenum Press, New York, pp. 139–143.
    1. Ichinose, M., Yahagi, N., Oka, M., Ikeda, H., Miki, K. and Omata, M. (2001) Screening for gastric cancer in Japan. In Cancer Screening. A practical guide for physicians (eds. Wu, G.Y. and Aziz, K.). Humana Press, Potowa, NJ, pp. 87–102.
    1. Miki K., Morita M., Sasasjima M., Hoshina R., Kanda E., Urita Y. (2003) Usefulness of gastric cancer screening using the serum pepsinogen test method. Am. J. Gastroenterol. 98, 735–739
    1. Dinis-Ribeiro M., Yamaki G., Miki K., Costa-Pereira A., Matsukawa M., Kurihara M. (2004) Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J. Med. Screen. 11, 141–147
    1. Miki K. (2006) Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 9, 245–253
    1. Miki K., Urita Y. (2007) Using serum pepsinogens wisely in a clinical practice. J. Dig. Dis. 8, 8–14
    1. Miki K., Fujishiro M., Kodashima S., Yahagi N. (2009) Long term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig. Endosc. 21, 78–81
    1. Nomura A.M.Y., Stemmermann G.N., Samloff I.M. (1980) Serum Pepsinogen I as a predictor of stomach cancer. Ann. Intern. Med. 93, 537–540
    1. Fukao A., Hisamichi S., Ohsato N., Fujino N., Endo N., Iha M. (1993) Correlation between the prevalence of gastritis and gastric cancer in Japan. Cancer Causes Control 4, 17–20
    1. Miki, K. (ed.) (1998) The Pepsinogen Method. Igakushoin, Tokyo (in Japanese).
    1. Correa P. (2010) Serum pepsinogen in gastric cancer screening. Dig. Dis. Sci. 55, 2123–2125
    1. Hatakeyama M. (2004) Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat. Rev. Cancer 4, 688–694
    1. Nomura A., Stemmermann G.N., Chyou P.H., Kato I., Perez P.G., Blaser M.J. (1991) Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N. Engl. J. Med. 325, 1132–1136
    1. Parsonnet J., Friedman G.D., Vandersteen D.P., Chang Y., Vogelman J.H., Orentreich N., Sibley R.K. (1991) Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325, 1127–1131
    1. International Agency for Research on Cancer (1994) Schistosomiasis, liver flukes and Helicobacter pylori. IARC Monogr. Eval. Carcinog. Risks Hum. 61, 177–240
    1. Fukuda H., Saito D., Hayashi S., Hisai H., Ono H., Yoshida S., Oguro Y., Noda T., Sato T., Katoh M., Terada M., Sugimura T. (1995) Helicobacter pylori infection, serum pepsinogen level and gastric cancer: a case-control study in Japan. Jpn. J. Cancer Res. 86, 64–71
    1. Uemura N., Mukai T., Okamoto S., Yamaguchi S., Mashiba H., Taniyama K., Sasaki N., Haruma K., Sumii K., Kajiyama G. (1997) Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 6, 639–642
    1. Kitahara F., Shimazaki R., Sato T., Kojima Y., Morozumi A., Fujino M.A. (1998) Severe atrophic gastritis with Helicobacter pylori infection and gastric cancer. Gastric Cancer 1, 118–124
    1. Graham D.Y. (2000) Helicobacter pylori infection is the primary cause of gastric cancer. J. Gastroenterol. 35 (Suppl. 12), 90–97
    1. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., Taniyama K., Sasaki N., Schlemper R.J. (2001) Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345, 784–789
    1. Watabe H., Mitsushima T., Yamaji Y., Okamoto M., Wada R., Kokubo T., Doi H., Yoshida H., Kawabe T., Omata M. (2005) Predicting the development of gastric cancer from combing Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 54, 764–768
    1. Fukase K., Kato M., Kikuchi S., Inoue K., Uemura N., Okamoto S., Terao S., Amagai K., Hayashi S., Asaka M., for the Japan Gast Study Group (2008) Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-lavel, randomized controlled trial. Lancet 372, 392–397
    1. Graham D.Y. (2009) Gastric cancer surveillance or prevention plus targeted surveillance. Jpn. J. Helicobacter Res. 10, 9–14
    1. Ito M., Takata S., Tatsugami M., Wada Y., Imagawa S., Matsumoto Y., Takamura A., Kitamura S., Matsuo T., Tanaka S., Haruma K., Chayama K. (2009) Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review. J. Gastroenterol. 44, 365–371
    1. Graham D.Y., Asaka M. (2010) Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J. Gastroenterol. 45, 1–8
    1. Mizuno S., Miki I., Ishida T., Yoshida M., Onoyama M., Azuma T., Habu Y., Inokuchi H., Ozasa K., Miki K., Watanabe Y. (2010) Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig. Dis. Sci. 55, 3132–3137
    1. Furuta T., Kaneko E., Baba S., Arai H., Futami H. (1997) Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori. Am. J. Gastroenterol. 92, 84–87
    1. Al-Assi M.T., Miki K., Walsh J.H., Graham D.P., Asaka M., Graham D.Y. (1999) Noninvasive evaluation of Helicobacter pylori therapy: Pole of fasting or postprandial gastrin, Pepsinogen I, Pepsinogen II, or serum IgG antibodies. Am. J. Gastroenterol. 94, 2367–2372
    1. Kawai T., Miki K., Ichinose M., Kenji Y., Miyazaki I., Kawakami K., Kataoka M., Yamagishi T., Sofuni A., Itoi T., Moriyasu F., Takagi Y., Aoki T., Matsubayashi J., Mukai K. (2007) Changes in evaluation of the pepsinogen test result following Helicobacter pylori eradication therapy in Japan. Inflammopharmacology 15, 31–35
    1. Suganuma T., Yamamoto Y., Uragami N., Fujisaki J., Hoshino E., Takahashi H., Miki K. (2009) A significant increase of fasting serum pepsinogen I/II ratio is a reliable biomarker for the successful Helicobacter pylori eradication in patients without peptic ulcer or gastric cancer. Gut 58 (Suppl. II), A401
    1. JRF PDT GC (ed.) (2009) Manual for the Gastric Cancer-Risk Screening (The ABC Method). Nanzan-do, Tokyo (in Japanese).
    1. Ichinose M., Miki K., Furihata C., Kageyama T., Niwa H., Oka H., Oda T., Matsushima T., Takahashi K. (1982) Radioimmunoassay of group II pepsinogen in human serum. Clin. Chim. Acta 122, 61–69
    1. Ichinose M., Miki K., Furihata C., Kageyama T., Hayashi R., Niwa H., Oka H., Matsushima T., Takahashi K. (1982) Radioimmunoassay of serum group I and group II pepsinogens in normal controls and patients with various disorders. Clin. Chim. Acta 126, 183–191
    1. Huang S.C., Miki K., Furihata C., Ichinose M., Shimizu A., Oka H. (1988) Enzyme-linked immunosorbent assays for serum pepsinogens I and II using monoclonal antibodies—with data on peptic ulcer and gastric cancer. Clin. Chim. Acta 175, 37–50
    1. Samloff I.M. (1971) Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 61, 185–188
    1. Samloff I.M., Liebman W.M. (1973) Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 65, 36–42
    1. Miki K., Ichinose M., Furihata C., Niwa H., Oka H., Oda T., Matsushima T. (1982) Potential peptic activity of pepsinogen of human gastroduodenal mucosa determined by fluorescent microassay method using albumin. Clin. Chim. Acta 121, 337–344
    1. Huang S.C., Miki K., Sano J., Ichinose M., Kawamura N., Oka H., Hirano K., Furihata C., Masugi Y., Takahashi K. (1988) Pepsinogen I and II in gastric cancer: An immunohistochemical study using monoclonal antibodies. Jpn. J. Cancer Res. (Gann) 79, 1139–1146
    1. Sano J., Miki K., Ichinose M., Kimura M., Kurokawa K., Aida T., Ishizaki M., Asano G., Masugi Y., Wong R.N.S., Takahashi K. (1989) In situ localization of pepsinogens I and II mRNA in human gastric mucosa. Acta Pathol. Jpn. 39, 765–771
    1. Kikuchi S., Wada O., Miki K., Nakajima T., Nishi T., Kobayashi O., Inaba Y. (1994) Serum pepsinogen as a new marker for gastric carcinoma among young adults. Cancer 73, 2695–2702
    1. Kato I., Miki K., Muñoz N., Vivas J.H., Lopez G., Peraza S., Carillo E., Castro D., Andrade O., Sanchez V., Cano E., Ramirez H., Muggli R., Benz M., Oliver W. (1995) Determinants of plasma pepsinogen levels in population at high risk for stomach cancer in Venezuela. Int. J. Cancer 62, 512–518
    1. Watanabe Y., Kurata J.H., Mizuno S., Mukai M., Inokuchi H., Miki K., Ozawa K., Kawai K. (1997) Helicobacter pylori infection and gastric cancer. A nested case-control study in a rural area of Japan. Dig. Dis. Sci. 42, 1383–1387
    1. Yoshihara M., Sumii K., Haruma K., Kiyohira K., Hattori N., Kitadai Y., Komoto K., Tanaka S., Kajiyama G. (1998) Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am. J. Gastroenterol. 93, 1090–1096
    1. Ozasa K., Kurata J.H., Higashi A., Hayashi K., Inokuchi H., Miki K., Tada M., Kawai K., Watanabe Y. (1999) Helicobacter pylori infection and atrophic gastritis. A nested case-control study in a rural town in Japan. Dig. Dis. Sci. 44, 253–256
    1. Namekata T., Miki K., Kimmey M., Fritsche T., Hughes D., Moore D., Suzuki K. (2000) Chronic atrophic gastritis and Helicobacter pylori infection among Japanese Americans in Seattle. Am. J. Epidemiol. 151, 820–830
    1. Plummer M., Vivas J., Fauchère J.L., Giudice G.D., Peña A.S., Ponzetto A., Lopez G., Miki K., Oliver W., Muñoz N. (2000) Helicobacter pylori and stomach cancer: a case-control study in Venezuela. Cancer Epidemiol. Biomarkers Prev. 9, 961–965
    1. Miki K. (2000) Clinico-pathological characteristics of “the pepsinogen method” -positive and negative gastric cancer. J. Gastroenterol. Cancer Screening 38, 292–293(in Japanese)
    1. Miki, K. (2004) Annual report 2001–2003 of the Research Committee of Effect and Efficiency of Gastric Cancer Screening, supported by a Grant-in-Aid for the Research from the Ministry of Health, Labour and Welfare, Japan, Tokyo (in Japanese).
    1. Ohata H., Kitauchi S., Yoshimura N., Mugitani K., Iwane M., Nakamura H., Yoshikawa A., Yanaoka K., Arii K., Tamai H., Shimizu Y., Takeshita T., Mohara O., Ichinose M. (2004) Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int. J. Cancer 109, 138–143
    1. Urita Y., Hike K., Torii N., Kikuchi Y., Kanda E., Sasajima M., Miki K. (2004) Serum pepsinogen as a predictor of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig. Dis. Sci. 49, 795–801
    1. Nomura A.M.Y., Kolonel L.N., Miki K., Stemmermann G.N., Wilkens L.R., Goodman M.T., Perez-Perez G.I., Blaser M.J. (2005) Helicobacter pylori, pepsinogen and gastric adenocarcinoma in Hawaii. J. Infect. Dis. 191, 2075–2081
    1. Ohata H., Oka M., Yanaoka K., Shimizu Y., Mukoubayashi C., Mugitani K., Iwane M., Nakamura H., Tamai H., Arii K., Nakata H., Yoshimura N., Takeshita T., Miki K., Mohara O., Ichinose M. (2005) Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography. Cancer Sci. 96, 713–720
    1. Oishi Y., Kiyohara Y., Kubo M., Tanaka K., Tanizaki Y., Ninomiya T., Doi Y., Shikata K., Yonemoto K., Shirota T., Matsumoto T., Iida M. (2006) The serum pepsinogen test as a predictor of gastric cancer: The Hisayama study. Am. J. Epidemiol. 163, 629–637
    1. Sasazuki S., Inoue M., Iwasaki M., Otani T., Yamamoto S., Ikeda S., Hanaoka T., Tsugane S., the Japan Public Health Center Study Group (2006) Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: A nested case-control study. Cancer Epidemiol. Biomarkers Prev. 15, 1341–1347
    1. Miki, K. (2007) Annual report 2004–2006 of the Research Committee of High Risk Strategy of Gastric Cancer Screening, supported by a Grant-in-Aid for the Research from the Ministry of Health, Labour and Welfare, Japan, Tokyo (in Japanese).
    1. Miki K. (2007) Endoscopic stomach cancer screening based on the high risk strategy. Gastroenterol. Endosc. 49, 2451–2461(in Japanese with English abstract)
    1. Yoshihara M., Hiyama T., Yoshida S., Ito M., Tanaka S., Watanabe Y., Haruma K. (2007) Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: A case-control study. Scand. J. Gastroenterol. 42, 760–764
    1. Yanaoka K., Oka M., Yoshimura N., Mukoubayashi C., Enomoto S., Iguchi M., Magari H., Utsunomiya H., Tamai H., Arii K., Yamamichi N., Fujishiro M., Takeshita T., Mohara O., Ichinose M. (2008) Risk of gastric cancer in asymptomatic middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int. J. Cancer 123, 917–926
    1. Yanaoka K., Oka M., Mukoubayashi C., Yoshimura N., Enomoto S., Iguchi M., Magari H., Utsunomiya H., Tamai H., Arii K., Ohata H., Fujishiro M., Takeshita T., Mohara O., Ichinose M. (2008) Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol. Biomarkers Prev. 17, 838–845
    1. Yanaoka K., Oka M., Ohata H., Yoshimura N., Deguchi H., Mukoubayashi C., Enomoto S., Inoue I., Iguchi M., Maekita T., Ueda K., Utsunomiya H., Tamai H., Fujishiro M., Iwane M., Takeshita T., Mohara O., Ichinose M. (2009) Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int. J. Cancer 125, 2697–2703
    1. Inui Y. (2009) Gastric cancer screening, past and future aspect: Reformation of gastric cancer screening, challenge from Takasaki city medical association. Gastro-Health Now 3, 1–3(in Japanese)
    1. Ito F. (2009) Let’s introduce gastric cancer-risk screening into population-based screening. Gastro-Health Now 8, 1–4(in Japanese)
    1. Tanaka H., Uemura N. (2010) Usefulness of gastric cancer screening using combination assay of the serum pepsinogen (PG) method and serum anti-Helicobacter pylori (H. pylori) IgG antibody, and the eradication therapy for all H. pylori infected subjects in Adachi ward. Gastroenterol. Endosc. 52 (Suppl. 2), 2411.(in Japanese)
    1. Inoue K., Fujisawa T., Haruma K. (2010) Assessment of degree of health of the stomach by concomitant measurement of serum pepsinogen and serum Helicobacter pylori antibodies. Int. J. Biol. Markers 25, 207–212
    1. Yanaoka K., Oka M., Yoshimura N., Deguchi H., Mukoubayashi C., Enomoto S., Maekita T., Inoue I., Ueda K., Utsunomiya H., Iguchi M., Tamai H., Fujisiro M., Nakamura Y., Tsukamoto T., Inada K., Takeshita T., Ichinose M. (2010) Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int. J. Cancer 126, 1467–1473
    1. Asaka M., Kimura T., Kudo M., Takeda H., Mitani S., Miyazaki T., Miki K., Graham D.Y. (1992) Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 102, 760–766
    1. Miki, K., Kodashima, S., Fujishiro, M. and Yahagi, N. (2009) A more efficient system for gastric cancer screening using the combination assay of serum anti-Helicobacter pylori IgG antibody and the serum pepsinogen levels. ACG 2009 Annual Scientific Meeting Symposia Sessions Abstract (2009 ACG Governors Award Recipient for Excellence in Clinical Research) p. 156.
    1. Kodashima S., Miki K., Fujishiro M., Yahagi N., Koike K. (2010) Usefulness of a new gastric cancer screening program using the combination assay of serum anti-Helicobacter pylori IgG antibody and the serum pepsinogen levels. Am. J. Gastroenterol. 105, S38
    1. Asaka M., Kimura T., Kato M., Kudo M., Miki K., Ogoshi K., Kato T., Tatsuta M., David Y.G. (1994) Possible role of Helicobacter pylori infection in early gastric cancer development. Cancer 73, 2691–2694
    1. Asaka M., Kato M., Kudo M., Katagiri M., Nishikawa K., Yoshida J., Takeda H., Miki K. (1995) Relationship between Helicobacter pylori infection, atrophic gastritis and gastric carcinoma in a Japanese population. Eur. J. Gastroenterol. Hepatol. 7 (Suppl. 1), S7–S10
    1. Asaka M., Kato M., Kudo M., Katagiri M., Nishikawa K., Koshiyama H., Takeda H., Yoshida J., Graham D.Y. (1996) Atrophic changes of gastric mucosa are caused by Helicobacter pylori infection rather than aging; studies in asymptomatic Japanese adults. Helicobacter 1, 52–56
    1. Asaka M., Kudo M., Kato M., Sugiyama T., Takeda H. (1998) Review article: long-term Helicobacter pylori infection—from gastritis to gastric cancer. Aliment. Pharmacol. Ther. 12 (Suppl. 1), 9–15
    1. Inoue K. (2010) We can tell the “degree of health” of the stomach (gastric cancer risk) by blood test. Gastro-Health Now 12, 1–3(in Japanese)
    1. Miki K. (2010) Present status and future aspects of gastric cancer-risk gastritis screening (ABC screening). Endoscopic Forum for digestive disease 26, 1–4(in Japanese with English abstract)

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅